TX-EMIST
2.11.2020 14:02:05 CET | Business Wire | Press release
EMist® Disinfection Solutions today announced the launch of the EX-7000 Tru Electrostatic™ Disinfectant Sprayer.
The EX-7000 is lightweight and ergonomic weighing in at just 14.9 pounds making it one-half lighter than other sprayers. Equipped with intelligent Charge Detect™ Technology, the EX-7000 electrostatic sprayer continuously detects the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue, ensuring the most comprehensive disinfectant coating in the industry, and reducing labor and chemical costs by 50 percent.
Disinfectant is first atomized, passes through an electrostatic-induction nozzle, charged using a bipolar power supply, and then discharged toward the target area. The bipolar supply causes the electrical charges to be alternatively redistributed, resulting in droplets having an excess of either positive or negative charges. These charged droplets are so attracted to the targeted area that they coat the sides, edges, and backside of surfaces.
EMist’s TruElectrostatic Disinfectant Sprayers are built on six core platforms, resulting in an electrostatic sprayer that provides 100 percent continuous electrostatic charge output, eliminates grounding, yielding superior, comprehensive coverage.
TruTechnology: EPIX Charge Detect Technology
Using EPIX Charge Detect Technology, the electrostatic sprayers continuously detect the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue. The discharged droplets wrap around surfaces. This wraparound effect creates an even, consistent and comprehensive coverage of chemical, reducing chemical and labor costs.
TruConfidence: Patented. Proven. Trusted.
Since the emergence of COVID-19, many companies have appeared overnight claiming they have electrostatic sprayers. When dealing with life-threatening pathogens, it’s critically important to know that the company you’re buying from is experienced, respected, and proven. EMist electrostatic sprayers are patented, backed by independent lab studies, used during the 2014 Ebola crisis, and developed by electrostatic industry veteran Mike Sides, who frequently works with the Department of Defense, Naval Entomology Center of Excellence, USDA, and the World Health Organization.
TruCharge: Best Performance
Electrostatic sprayer polarity matters. Most surfaces have a negative or neutral charge (the earth itself is negative). Per the EPA, electrostatic sprayers should impart a positive charge so that the positively charged disinfectant droplets are attracted to targeted negative or neutral surfaces. Positively charged droplets increase droplet adhesion and wrap.
TruDesign: Safer Operation
When spraying big areas, big buildings, or tight spaces, a cordless sprayer allows you to maneuver and move about freely. EMist sprayers are ergonomic, lightweight, and cordless. That means operators can take the sprayer to where the work needs to be done rather than relying on wall outlets at the work site. Portability is a clear advantage for any user who needs to go where the work is to get the job done right.
TruAssurance: User Safety
Per the EPA, electrostatic disinfectant sprayers should have a median droplet size greater than 40 microns. Droplets must be large enough to resist evaporation and drift but small enough that the droplets can change their trajectory when it comes close to a target. Most competitor sprayers produce droplets of less than 40 microns making them highly drift-prone and increasing user inhalation concerns. EMist sprayers maintain a median droplet size of 75 microns.
TruCost: Lower Total Cost of Ownership
Based on the need to disinfect large areas, manual application of disinfectants is a thing of the past. Electrostatic application is the new normal. Customers using EMist systems typically see up to 50 percent reduction in labor and chemical costs. Competitively priced, advanced and patented electrostatic technology, and proven performance provide an overall lower total cost of ownership.
EMist has announced a reservation program for purchasers who want to secure their units in December. The company will begin taking refundable $50 reservations on its official website starting on November 2 at 8 a.m. Central Time. The EX-7000 is available through EMist distributors at a list price of $3,995 USD.
About EMist
Headquartered in Fort Worth, Texas, EMist develops intelligent electrostatic disinfectant sprayers that make spaces healthier. For more information, visit EMist.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005026/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 17:20:00 CEST | Press release
Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 17:00:00 CEST | Press release
Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 Daiichi Sankyo Europe’s commitment to "care for every heartbeat" is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
